Nerve conduction testing for people with rheumatoid arthritis taking baricitinib
Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib
This project will test whether nerve conduction testing detects peripheral nerve changes in adults with rheumatoid arthritis who are taking baricitinib.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Drugs / interventions | Baricitinib |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06977035 on ClinicalTrials.gov |
What this trial studies
Adults with rheumatoid arthritis who meet standard classification criteria and are taking the JAK inhibitor baricitinib will undergo nerve conduction studies to measure sensory nerve action potentials (SNAPs) and compound muscle action potentials (CMAPs). The testing will characterize sensory and motor nerve function along peripheral nerve pathways. Eligible, consenting participants seen at the site will have standardized NCS procedures performed and results compared to expected normative values and known neuropathy patterns. The protocol excludes patients with other causes of neuropathy such as diabetes or other rheumatologic/collagen diseases to isolate findings related to RA and baricitinib exposure.
Who should consider this trial
Good fit: Adults aged 18 to 65 with rheumatoid arthritis who meet the 2010 ACR/EULAR criteria, are taking baricitinib, and can cooperate with testing are the ideal candidates.
Not a fit: People younger than 18 or older than 65, or those with other causes of neuropathy such as diabetes or other rheumatologic/collagen diseases, are unlikely to benefit from the findings.
Why it matters
Potential benefit: If successful, the work could help detect early or subclinical peripheral nerve changes in patients on baricitinib so clinicians can monitor or adjust treatment sooner.
How similar studies have performed: Nerve conduction studies are a well-established method for detecting peripheral neuropathy, but their specific use to characterize neuropathy in patients on baricitinib is relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients fulfill the 2010 ACR/EULAR classification criteria of RA 2. Age above 18 years old. 3. Patient cooperative and can answer questions Exclusion Criteria: 1. Other rheumatologic or collagen diseases. 2. Age below 18 years and above 65 years. 3. Uncooperative patients. 4. Patients with other causes of peripheral neuropathy as Diabetes mellitus.
Where this trial is running
Sohag
- Sohag University Hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Sara K Mohamed, Resident
- Email: sara.khairy@med.sohag.edu.eg
- Phone: 01155791113
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.